Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies worldwide. Its product portfolio includes aesthetic device platforms, including Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Velocity and Venus Epileve, a diode laser device for hair removal, permanent hair reduction, and treatment of ingrown hair; and Venus Fiore that is used for the treatment of vaginal canal, labia skin tightening, and mons pubis. The company also offers Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin; Venus Freeze Plus, a noninvasive device used in dermatologic and general surgical procedures for females for the noninvasive treatment of moderate to severe facial wrinkles and rhytides; Venus Bliss, a device is used for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance. In addition, it provides NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system; and ARTAS and ARTAS iX, a robotic systems to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
IPO Year: 2017
Exchange: NASDAQ
Website: venusconcept.com
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2024. Second Quarter 2024 Summary & Recent Progress: Company continues to execute against Transformational Plan Cash used in operations of $1.3 million, down 37% year-over-year and down 54% quarter-over-quarter Total revenue of $16.6 million, down 17% year-over-year, but in-line with second quarter estimate of at "least $16.5 million". Gross margin up 62 basis points year-over-year to 71.5%, combined with a 13% decrease in operating expenses year-over-year, dri
TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has received a medical device license issued by Health Canada to market the Venus Bliss MAX system in Canada. The Venus Bliss MAX was first available in the United States in early 2022 and subsequently offered in approved jurisdictions around the world. The Venus Bliss MAX is a 3-in-1 body shaping solution featuring three of Venus Concept's market leading technologies in one complete platform, including diode laser for Fat Reduction treatments, our proprietary (MP)2 applicator that combines Multi-Polar Radio F
TORONTO, July 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2024 financial results will be released before the market opens on Tuesday, August 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on August 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13747737. A live webcast of the call will also be provided on the investor relations section of the Company's webs
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announces the successful completion of its NEXThetics events held across several major cities in North America. NEXThetics events bring together Venus Concept's network of aesthetic leaders and practitioners and have seen a significant increase in popularity and attendance. Since our pilot events, the Company has hosted thousands of registrants, including its largest gathering to date in Houston, Texas on June 22, 2024. "NEXThetics Houston was an outstanding event, centering on the core principles of the latest technology, networking
TORONTO, June 17, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that it has entered a new strategic resurfacing and skin tightening device supply arrangement with Skin Laundry Holdings, Inc. ("Skin Laundry"). The supply arrangement included an initial order for Venus Viva ("Viva") devices for their locations across the United States and the associated Viva tips consumable to complete the procedures. Skin Laundry is placing the devices throughout their chain of clinics and plans to perform thousands of skin resurfacing treatments per month using Venus Concept's proprietary (MP)2 Nan
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced that on June 4, 2024, it was notified by the Nasdaq Stock Market LLC ("Nasdaq") that the Company had regained compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) ("Minimum Equity Requirement"). Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor through June 4, 2025. The Nasdaq Staff originally issued the Company a deficiency notice on May 31, 2023, citing that stockholders' equity as reported in the Company's Quarterly Report
TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has received a medical device license issued by Health Canada to market the Venus Versa Pro system in Canada. The Venus Versa Pro is a comprehensive aesthetic platform which houses the latest technologies in one device to offer a total skin rejuvenation experience. The synergizing of Intense Pulsed Light (IPL) with SmartPulse™, NanoFractional Radio Frequency with SmartScan™, and Venus Concept's proprietary (MP)2 technology enable clinicians to provide a range of procedures to enhance skin tone, improve tightne
TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that, on May 24, 2024, the Company exchanged $35.0 million of its senior debt held by affiliates of Madryn Asset Management, LP ("Madryn") for 576,986 shares of newly-created Series Y preferred stock. Each share of Series Y preferred stock is convertible into common stock on a 1-for-100 basis at the option of the holder at any time, or automatically upon the Company's completion of a $30.0 million common equity raise, subject to certain other conditions. The debt-to-equity exchange represents a significant reduction in
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2024. First Quarter 2024 Summary & Recent Progress: Company continues to execute against Transformational Plan Cash used in operations of $2.9 million, down 51% year-over-year from $5.9 millionCash system revenue in first quarter 2024 represented approximately 75% of total systems and subscriptions revenue, compared to 66% in the prior year period Total revenue of $17.5 million, down 15% year-over-year but exceeded first quarter estimate of at least $
TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that on April 23, 2024, its existing Main Street Lending Program Loan ("MSLP Loan") was purchased by affiliates of Madryn Asset Management, LP ("Madryn") for an undisclosed amount from the City National Bank of Florida ("CNB") with the consent of the Company (the "MSLP Loan Purchase"). Following close of the MSLP Loan Purchase, Venus Concept and Madryn entered into a Loan and Security Agreement ("Madryn Loan Agreement"), dated April 23, 2024, pursuant to which Madryn provides an aggregate principal amount of up to $5.
S-8 - Venus Concept Inc. (0001409269) (Filer)
10-Q - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
SD - Venus Concept Inc. (0001409269) (Filer)
8-K/A - Venus Concept Inc. (0001409269) (Filer)
TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume
TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in
TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med
TORONTO, July 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2024 financial results will be released before the market opens on Tuesday, August 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on August 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13747737. A live webcast of the call will also be provided on the investor relations section of the Company's webs
TORONTO, April 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 15, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2024, to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13745887. A live webcast of the call will also be provided on the investor relations section of the Company's website
TORONTO, April 01, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023. Fourth Quarter and Fiscal Year 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan and achieved primary objective of reducing cash burn by over 50% vs. prior year Cash used in operations for fiscal year 2023 of $12.9 million, down 52% year-over-year, from $27.0 million in the prior year periodCash system revenue for fiscal year 2023 represented approximately 67% of total systems and subscriptions revenu
TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2023 financial results will be released before the market opens on Monday, April 1, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on April 1, 2024 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13744647. A live webcast of the call will also be provided on the investor relations section of the
TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2023. Third Quarter 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan Total revenue of $17.6 million, down $3.9 million, or 18%, year-over-yearCash system revenue represented approximately 69% of total systems and subscriptions revenue, compared to 59% in the prior year periodOperating expenses of $18.9 million, including approximately $0.8 million of costs related to restructuring activities, down $5.9 million, or
TORONTO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2023 financial results will be released after the market closes on Tuesday, November 14, 2023. Management will host a conference call at 5:00 p.m. Eastern Time on November 14, 2023 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13741931. A live webcast of the call will also be provided on the investor relations section of the Company's w
TORONTO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2023. Second Quarter 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan Total revenue of $20.1 million, down $7.2 million, or 26%, year-over-yearCash system revenue represented approximately 74% of total systems and subscriptions revenue, compared to 49% in the prior year periodOperating expenses of $20 million, including approximately $0.4 million of costs related to restructuring activities, down $6.2 mil
TORONTO, July 05, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2023 financial results will be released after the market closes on Monday, August 14, 2023. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2023 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13739854. A live webcast of the call will also be provided on the investor relations section of the Company's websi
TORONTO, May 15, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2023. First Quarter 2023 Summary & Recent Highlights: Company continues to execute against Transformational Plan Total revenue of $20.5 million, down $5.9 million, or 22%, year-over-yearCash system revenue represented approximately 66% of total systems and subscriptions revenue, compared to 53% in the prior year periodOperating expenses of $21.9M, including approximately $0.9 million of costs related to restructuring activities, down $3.3M or 13% year-over-yearCash use
TORONTO, April 11, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2023 financial results will be released before the market opens on Monday, May 15, 2023. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2023 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13737854. A live webcast of the call will also be provided on the investor relations section of the Company's website a
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed refractory chronic lymphocytic leukemia. Nurix Therapeutics shares jumped 12.1% to $17.01 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) rose 89.4% to $6.61 in pre-market trading after surging 24% on Friday. Scinai Immunotherapeutics, last week, received a non-binding Letter of Intent from the European Investment Bank for converting loan into equity. Interactive Strength Inc. (NASDAQ:TR
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. Venus Concept (NASDAQ:VERO) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. Tharimmune (NASDAQ:THAR) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. Kineta (NASDAQ:KA) shares moved upwards by
Skin Laundry is placing the devices throughout their chain of clinics and plans to perform thousands of skin resurfacing treatments per month using Venus Concept's proprietary (MP)2 NanoFractional RF Technology with SmartScan, which provides clinically validated efficacy in both resurfacing and tightening. Venus Concept's (MP)2 technology provides both RF and PEMF for optimal collagen and elastin formation with over 9,000 systems installed globally.
Gainers Vaxart (NASDAQ:VXRT) shares increased by 146.7% to $1.85 during Thursday's after-market session. The market value of their outstanding shares is at $327.1 million. Venus Concept (NASDAQ:VERO) stock rose 10.32% to $0.95. The company's market cap stands at $6.0 million. Vincerx Pharma (NASDAQ:VINC) stock moved upwards by 5.99% to $0.73. The market value of their outstanding shares is at $21.5 million. Kintara Therapeutics (NASDAQ:KTRA) shares rose 5.82% to $0.2. The company's market cap stands at $10.9 million. Beyond Air (NASDAQ:XAIR) shares moved upwards by 5.64% to $1.31. The company's market cap stands at $60.1 million. Soligenix (NASDAQ:SNGX) stock rose 5.42% to $4.38. The m
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNCY) stock increased by 6.09% to $0.69. The company's market cap stands at $26.1 million. Venus Concept (NASDAQ:VERO) stock increased by 5.71% to $1.11. The company's market cap stands at $7.0 million. Gossamer Bio (NASDAQ:GOSS) stock moved upwards by 4.99% to $0.54. The market value of their outstanding shares is at $121.2 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by 4.86% to $5.82. The market value of their outstanding shares is at $185.1 million. Poseida Therapeuti
Gainers Calidi Biotherapeutics (AMEX:CLDI) shares rose 29.7% to $0.25 during Monday's pre-market session. The market value of their outstanding shares is at $16.0 million. Entero Therapeutics (NASDAQ:ENTO) shares rose 22.41% to $2.99. The company's market cap stands at $8.2 million. TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 19.09% to $1.31. The company's market cap stands at $8.6 million. Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 15.3% to $0.47. The market value of their outstanding shares is at $33.2 million. CERo Therapeutics Hldgs (NASDAQ:CERO) shares moved upwards by 15.12% to $0.78. The company's market cap stands at $11.6 million. Co-Diagnostics (NASDAQ:
Shares of KKR & Co. Inc. (NYSE:KKR) rose sharply in today's pre-market trading after it was announced the company will join the S&P 500. S&P Dow Jones Indices announced late Friday changes to various S&P indices, coinciding with the quarterly rebalance. KKR will take the place of Comerica Inc. (NYSE:CMA) in the broader gauge. KKR & Co. shares jumped 10.4% to $108.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) rose 165% to $5.05 in today's pre-market trading. New Horizon Aircraft Ltd. (NASDAQ:HOVR) gained 90.1% to $1.37 in pre-market trading after declining around 8% on Frid
Venus Concept Inc. (NASDAQ:VERO) shares are experiencing a surge in trading activity Friday due to the company’s recent announcement that it has regained compliance with Nasdaq’s minimum equity rule. What To Know: Venus Concept saw its stock price soar by 126.7% in pre-market trading on Friday on continued momentum after the announcement on Thursday. This compliance, achieved after a significant debt-to-equity transaction, has fueled investor confidence and propelled the stock upward. Related Link: Venus Concept Stock Soars 127% Premarket After Regaining Nasdaq Compliance The company confirmed on June 4 that it had satisfied the stockholders’ equity requirement, after receiving a d